Novartis AG
137.48USD
-0.2200 (-0.16%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $2.23▲ | $2.16 | 1 | 0 |
| Next quarter | $2.1▼ | $2.31 | 0 | 1 |
| Current year | $8.8▼ | $8.84 | 5 | 1 |
| Next year | $9.81▼ | $9.93 | 2 | 2 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $2.15 | $2.41 | +0.26 (+12.2%) |
| 2026-03-31 | $2.07 | $1.99 | -0.08 (-3.7%) |
| 2025-12-31 | $2 | $2.03 | +0.03 (+1.3%) |
| 2025-09-30 | $2.31 | $2.25 | -0.06 (-2.6%) |
68 ratings from 24 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | $143 $170 | Mar 26, 2026 |
| Barclays | Upgraded from Underweight | Equal-Weight | — | Jan 6, 2026 |
| JP Morgan | Upgraded from Neutral | Overweight | — | Dec 8, 2025 |
| Goldman Sachs | Downgraded from Neutral | Sell | $119 $118 | Sep 12, 2025 |
| UBS | Downgraded from Buy | Neutral | — | Feb 13, 2025 |
| Erste Group | Downgraded from Buy | Hold | — | Nov 19, 2024 |
| BMO Capital | Maintained | Market Perform | $118 $120 | Oct 30, 2024 |
| B of A Securities | Downgraded from Buy | Neutral | $135 $130 | Sep 11, 2024 |
| Goldman Sachs | Downgraded from Buy | Neutral | $119 $121 | Sep 5, 2024 |
| Jefferies | Downgraded from Buy | Hold | — | Sep 3, 2024 |
| Jefferies | Maintained | Buy | $121 $122.5 | Jul 2, 2024 |
| BMO Capital | Maintained | Market Perform | $114 $116 | Apr 24, 2024 |
| BMO Capital | Initiated | Market Perform | $114 | Feb 23, 2024 |
| Morgan Stanley | Initiated | Equal-Weight | $114 | Jan 23, 2024 |
| Morgan Stanley | Upgraded from Underweight | Equal-Weight | — | Sep 25, 2023 |
| Wolfe Research | Downgraded from Outperform | Peer Perform | — | May 9, 2022 |
| Exane BNP Paribas | Downgraded from Outperform | Neutral | — | Dec 6, 2021 |
| Bryan Garnier | Downgraded from Buy | Neutral | — | Dec 3, 2021 |
| Deutsche Bank | Downgraded from Hold | Sell | — | Sep 20, 2021 |
| Argus Research | Downgraded from Buy | Hold | — | Mar 10, 2021 |
| Cowen & Co. | Downgraded from Outperform | Market Perform | $110 $105 | Feb 1, 2021 |
| Deutsche Bank | Initiated | Buy | — | Jan 15, 2021 |
| Morgan Stanley | Upgraded from Equal-Weight | Overweight | — | Sep 1, 2020 |
| Guggenheim | Downgraded from Buy | Neutral | — | Feb 25, 2020 |
| Guggenheim | Upgraded from Neutral | Buy | — | Apr 25, 2019 |
No analyst notes on NVS yet.
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 2 | 5 | 2 | 0 | Hold2.50 |
| 1 mo ago | 3 | 2 | 4 | 2 | 1 | Hold2.67 |
| 2 mo ago | 3 | 2 | 4 | 2 | 1 | Hold2.67 |
| 3 mo ago | 3 | 2 | 5 | 2 | 0 | Hold2.50 |